 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...4344454647484950515253...235236» |
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
A NOVEL RADIOMICS-BASED MODEL TO PREOPERATIVELY PREDICT RESECTION MARGIN (R0 VS. R1) AND OVERALL SURVIVAL IN NEOADJUVANT-TREATED PDAC PATIENTS (Adams) - Jun 20, 2023 - Abstract #APCM2023APCM_51;
Our newly retrospectively, albeit independently validated, radiomic-based model was successfully able to assess resection margin (R0 vs. R1) as well as OS in PDAC patients in preoperative settings. This study paves the way for personalizing surgical treatment for PDAC patients.
- ORGANOTYPIC SLICE CULTURES FOR EX VIVO THERAPY PREDICTION IN PANCREATIC CANCER (Adams) - Jun 20, 2023 - Abstract #APCM2023APCM_50;
The immediate establishment after surgical resection, allows a rapid ex vivo therapy response assessment. Most importantly, tumor components such as tumor cells, stromal cells and immune cells can be assessed distinctly.
- 5-fluorouracil / Generic mfg.
GENOMIC BIOMARKERS ASSOCIATED WITH RESPONSE TO INDUCTION CHEMOTHERAPY IN PATIENTS WITH LOCALIZED PANCREATIC DUCTAL ADENOCARCINOMA (Adams) - Jun 20, 2023 - Abstract #APCM2023APCM_37;
SMAD4 alterations were uniquely associated with more frequent development of metastasis and lower probability of reaching surgical resection with induction FOLFIRINOX, which was not observed with induction gemcitabine/nab-paclitaxel. Prospective evaluation of SMAD4 as a predictive genomic biomarker is warranted to guide first-line treatment selection.
- DISSECTING THE ROLE OF NODAL METASTASES LOCATION IN PANCREATODUODENECTOMY AFTER NEOADJUVANT TREATMENT FOR CANCER: RESULTS FROM A PROSPECTIVE LYMPHADENECTOMY PROTOCOL (Adams) - Jun 20, 2023 - Abstract #APCM2023APCM_35;
Examining second-echelon LNs does not improve the staging process substantially. Yet, second-echelon involvement is prognostically relevant, as well as metastases to station 8 and jejunal mesentery LNs.
- 5-fluorouracil / Generic mfg.
WHY THE TREATMENT SEQUENCE MATTERS: INTERPLAY BETWEEN CHEMOTHERAPY CYCLES RECEIVED, CUMULATIVE DOSE INTENSITY, AND SURVIVAL IN RESECTED EARLY-STAGE PANCREAS CANCER (Adams) - Jun 20, 2023 - Abstract #APCM2023APCM_25;
Neoadjuvant therapy was associated with an increased odds of receiving ?67% of cycles and ?56% cumulative. Given that many patients fail to initiate or complete adjuvant chemotherapy after up-front pancreatectomy for PDAC, a neoadjuvant approach should be considered regardless of tumor location in patients with potentially resectable PDAC.
- 5-fluorouracil / Generic mfg.
NATIONWIDE USE AND OUTCOME OF SURGERY FOR LOCALLY ADVANCED PANCREATIC CANCER FOLLOWING INDUCTION CHEMOTHERAPY (Adams) - Jun 20, 2023 - Abstract #APCM2023APCM_19;
P
In the study period, resections of LAPC following induction chemotherapy were very rarely performed in The Netherlands, of which mostly in the 3 very high-volume centers, but with acceptable OS. A nationwide training and implementation program might improve the use and outcome of LAPC resections and started in 2021 (PREOPANC4 project: NCT05524090).
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
SURGICAL EXPLORATION WITHOUT RESECTION IN LAPC FOLLOWING (M)FOLFIRINOX (Adams) - Jun 20, 2023 - Abstract #APCM2023APCM_14;
A nationwide training and implementation program might improve the use and outcome of LAPC resections and started in 2021 (PREOPANC4 project: NCT05524090). Even in experienced hands, about
- | oxaliplatin / Generic mfg.
Journal: SUMO2/3 promotes the progression and oxaliplatin resistance of colorectal cancer through facilitating the SUMOylation at Ku80-K307. (Pubmed Central) - Jun 20, 2023
Notably, Ku80 undergoes SUMOylation at K307 by SUMO2/3 and this correlated with apoptosis in CRC cells suffering oxaliplatin stress. Collectively, we found that SUMO2/3 plays a specific role in CRC tumorigenesis and acts through Ku80 SUMOylation which is linked with the development of CRC-oxaliplatin resistance.
- ||| Cyramza (ramucirumab) / Eli Lilly
P2/3 data, Journal, Metastases: Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415). (Pubmed Central) - Jun 20, 2023
P2/3
This offers a rationale for the phase III trial. If the RAMIRIS III trial transfers and confirms the results, they will affect the current treatment guidelines, recommending the combination therapy of FOLFIRI-Ram for taxane-pretreated patients with advanced GEA.
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Retrospective data, Review, Journal, Metastases: Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis. (Pubmed Central) - Jun 20, 2023
According to the NMA results, NALIRI?+?5-FU, and folinic acid may represent the best second-line treatment for improved survival outcomes in mPDAC. Further evidence from prospective trials is needed to determine the best treatment option for this group of patients.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, Surgery, Metastases: "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancreatology (IAP) & Japan Pancreas Society (JPS) 2022. (Pubmed Central) - Jun 20, 2023
This article summarizes the agreement during the discussion amongst the experts in the meeting. We hope that this will serve as a foundation for future international collaboration and recommendations for future guidelines.
- | chloroquine phosphate / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Tetrahydrobenzo[h]quinoline derivatives as a novel chemotype for dual antileishmanial-antimalarial activity graced with antitubercular activity: Design, synthesis and biological evaluation. (Pubmed Central) - Jun 19, 2023
We hope that this will serve as a foundation for future international collaboration and recommendations for future guidelines. Their antifolate mechanism was confirmed via the ability of folic and folinic acids to reverse the antileishmanial activity of these compounds, comparably to Lm-PTR1 inhibitor trimethoprim...The most active compounds were further screened in vitro against the chloroquine resistant strain P. falciparum, (RKL9) and showed IC value range of 0.0198-0.096
- | Journal: Gene network analysis of oxaliplatin-resistant colorectal cancer to target a crucial gene using chitosan/hyaluronic acid/protamine polyplexes containing CRISPR-Cas9. (Pubmed Central) - Jun 19, 2023
Following the efficient gene delivery, sequences in CRISPR/Cas9 target sites were altered, ERCC1 was downregulated, and drug sensitivity was successfully restored in oxaliplatin-resistant cells. Findings indicate that CS/HA/PS/CRISPR polyplexes provide a potential strategy for delivering cargo and targeting oxaliplatin resistance-related gene to manipulate drug resistance as a rising concern in cancer therapeutic approaches.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, HEOR, Mismatch repair, Microsatellite instability, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancerF. (Pubmed Central) - Jun 19, 2023
Findings indicate that CS/HA/PS/CRISPR polyplexes provide a potential strategy for delivering cargo and targeting oxaliplatin resistance-related gene to manipulate drug resistance as a rising concern in cancer therapeutic approaches. Pembrolizumab obtained a cost per month progression-free survival gained ranged from 6471
- | methotrexate / Generic mfg.
Journal: Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study. (Pubmed Central) - Jun 19, 2023
The need for effective, safe and rapid treatment for the reduction of MTX toxic levels and the improvement of monitoring methods were noted by experts as urgent needs. Further observational studies to validate these results would be needed.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: A Long-Term Survival Case of Multiple Liver Metastases from Colon Cancer Treated with Intensive Multimodality Therapy (Pubmed Central) - Jun 19, 2023
A right lobectomy was performed for these 2 lesions, and then 16 more courses of FOLFIRI chemotherapy were performed. The chemotherapy was discontinued, and the patient was then followed up as an outpatient without chemotherapy; there has been no recurrence.
- | Trial completion date, Trial primary completion date: SU2C ACT3: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (clinicaltrials.gov) - Jun 18, 2023
P3, N=500, Recruiting, Sponsor: Massachusetts General Hospital
The chemotherapy was discontinued, and the patient was then followed up as an outpatient without chemotherapy; there has been no recurrence. Trial completion date: Feb 2023 --> Apr 2026 | Trial primary completion date: Feb 2022 --> Apr 2025
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open, Trial completion date, Trial primary completion date, Metastases: SINAI: Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jun 18, 2023
P2, N=60, Recruiting, Sponsor: National Taiwan University Hospital
Trial completion date: Feb 2023 --> Apr 2026 | Trial primary completion date: Feb 2022 --> Apr 2025 Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Xpovio (selinexor) / Karyopharm
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Jun 18, 2023
P1, N=221, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Recruiting --> Active, not recruiting | N=390 --> 221 | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Metastases: HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC (clinicaltrials.gov) - Jun 18, 2023
P2, N=32, Completed, Sponsor: Peking University
Recruiting --> Active, not recruiting | N=390 --> 221 | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024 Recruiting --> Completed | Trial primary completion date: Jul 2022 --> May 2023
- ||||| Clinical: 🔥First-line systemic treatment strategies in patients with initially unresectable #CRC liver metastases (CAIRO5) @TheLancetOncol https://t.co/pmBSQKVw7N 🏅right-sided, mRAS or mBRAF CRC: FOLFOXIRI + Beva 🏅left-sided, RAS & BRAF WT CRC: FOLFOX/FOLFIRI + Beva or Pani @myESMO… https://t.co/OJzLIFWbKM (Twitter) - Jun 15, 2023
- ||||| Clinical: 🔥First-line systemic treatment strategies in patients with initially unresectable #CRC liver metastases (CAIRO5) @TheLancetOncol https://t.co/pmBSQKVw7N 🏅right-sided, mRAS or mBRAF CRC: FOLFOXIRI + Beva 🏅left-sided, RAS or BRAF WT CRC: FOLFOX/FOLFIRI + Beva or Pani @myESMO… https://t.co/x4jKFFJc2I (Twitter) - Jun 15, 2023
- || tilatamig samrotecan (AZD9592) / AstraZeneca
Trial completion date, Trial primary completion date, Monotherapy: EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov) - Jun 15, 2023
P1, N=108, Recruiting, Sponsor: AstraZeneca
Recruiting --> Completed | Trial primary completion date: Jul 2022 --> May 2023 Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Jan 2025
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion date, Metastases: AIO-NIFE-trial: Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer (clinicaltrials.gov) - Jun 15, 2023
P2, N=93, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Jan 2025 Trial completion date: Jul 2022 --> Jan 2025
- |||| Vectibix (panitumumab) / Amgen
Trial completion: PanaMa: Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 15, 2023
P2, N=387, Completed, Sponsor: AIO-Studien-gGmbH
Trial completion date: Jul 2022 --> Jan 2025 Active, not recruiting --> Completed
- ||| Vectibix (panitumumab) / Amgen
Trial completion: FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) (clinicaltrials.gov) - Jun 15, 2023
P2, N=93, Completed, Sponsor: AIO-Studien-gGmbH
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Journal, Combination therapy: Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer. (Pubmed Central) - Jun 14, 2023
Active, not recruiting --> Completed These results support the combination of cytotoxic chemotherapy and molecular targeted therapy as a promising therapeutic approach in the first-line treatment of BRAFV600E mCRC.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. (Pubmed Central) - Jun 14, 2023
DetermaIO may be useful to predict benefit of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in mCRC. The exploratory IOOPT cut-point should be validated in independent mCRC cohorts.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Very much! About 150X more expensive than FOLFIRINOX (Twitter) - Jun 13, 2023
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: 20/21 #TumorBoardTuesday 🥁roll please... ✅Dr. Schrag🗣️the LONG awaited PROSPECT trial, which was designed on the premise that rectal Ca Pts could be cured WITHOUT pelvic☢️ ➡️Pts were randomized to TNT (with FOLFOX) vs. Chemo☢️ ➡️BUT Pts w/ a good response to chemo were SPARED☢️ (Twitter) - Jun 13, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
19/21 #TumorBoardTuesday ✅To put the PROSPECT trial in context, Dr. Conroy🗣️the PRODIGE 23 trial of TNT with FOLFIRINOX vs. Chemo☢️ for rectal ➡️TNT⬆️Disease-free survival compared to Chemo☢️ & ➡️TNT⬆️OS compared to Chemo☢️ (Twitter) - Jun 13, 2023
- ||||| Clinical, Metastases: 16/21 #TumorBoardTuesday ➡️Finally, moving on to the management of advanced #colorectalcancer & rectal Ca, which is getting very complicated😲 ➡️First, Dr. Antoniotti 🗣️an update of the AtezoTRIBE trial in which patients with mCRC were randomized to FOLFOXIRI-Bev +/- Atezo (Twitter) - Jun 13, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Absolutely. Patients have long-term toxicity from FOLFOX too. (Twitter) - Jun 13, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Clinical data: Nobody has seemed to explain why one would choose a more toxic regimen (additional FOLFOX) with no improvement in clinical outcomes vs chemoRT. Why is it that avoiding RT seems to be its own reward, rather than improving any clinical outcome? (Twitter) - Jun 13, 2023
- | 5-fluorouracil / Generic mfg.
Journal: The effects of Ankaferd hemostat on preventing oral mucositis in colorectal cancer patients receiving chemotherapy. (Pubmed Central) - Jun 12, 2023
P=N/A
It was determined that Ankaferd hemostat is effective in preventing oral mucositis due to chemotherapy in adult patients diagnosed with colorectal cancer. In addition, it has been suggested to conduct new studies on the effectiveness of Ankaferd hemostat in the prevention of mucositis in different groups.
- | Journal: FLOT or CROSS for gastroesophageal junction cancers (Pubmed Central) - Jun 12, 2023
Several factors must be borne in mind when making the optimal choice for a patient. Some of these include surgical candidacy, tolerance to chemotherapy, eligibility for radiation (RT) as well as institutional preferences.
- | 5-fluorouracil / Generic mfg.
Journal, Metastases: Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer. (Pubmed Central) - Jun 12, 2023
Some of these include surgical candidacy, tolerance to chemotherapy, eligibility for radiation (RT) as well as institutional preferences. This study determined that FOLFIRI and paclitaxel+carboplatin treatments have similar OS, PFS, and side effect profiles in subsequent
- || Retrospective data, Review, Journal, Metastases: ASO Visual Abstract: FOLFIRINOX or Gemcitabine Based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-Institutional, Patient-Level Meta-Analysis and Systematic Review. (Pubmed Central) - Jun 12, 2023
This study determined that FOLFIRI and paclitaxel+carboplatin treatments have similar OS, PFS, and side effect profiles in subsequent No abstract available
- | irinotecan / Generic mfg.
Journal, Patient reported outcomes: Multicentre, interventional, single-arm study protocol of telemonitored circadian rhythms and patient-reported outcomes for improving mFOLFIRINOX safety in patients with pancreatic cancer (MultiDom, NCT04263948). (Pubmed Central) - Jun 11, 2023
P=N/A
The data will be disseminated at conferences and in peer-reviewed journals and will support large-scale randomised evaluation. NCT04263948 and ID RCB-2019-A00566-51.
- |||| Clinical, Metastases: Congrats~🎊 to patients with advanced GEJ & #GastricCancer & #SPOTLIGHT team @KoheiShitara @FlorianLordick @ILSONDavid #zolbetuximab + mFOLFOX6 in tumors #HER2 (-) #CLDN18.2 show ⬆️OS & PFS📈 vs SOC mFOLFOX6 met endpoints HR 0.75; mOS 18.2m vs 15.5m, p=0.005 🖊️87% had PD-L1 CPS<5 (Twitter) - Jun 11, 2023
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Cholecystoenteric Stent-Related Complications: Rendering the Inoperable Patient Operable. (Pubmed Central) - Jun 10, 2023
With the increasing utility of cholecystoenteric stents, surgeons should be aware of the complications and have a plan for managing the duodenotomy or gastrotomy. Shared-medical decision-making involving surgeons should be applied when placing these stents.
- || Review, Journal: Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going. (Pubmed Central) - Jun 10, 2023
Shared-medical decision-making involving surgeons should be applied when placing these stents. The future challenge could be to identify only selected patients who will really benefit from upfront surgery despite a combination of NAD and surgery.
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Retrospective data, Journal, Metastases: Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis. (Pubmed Central) - Jun 10, 2023
First-line irinotecan-based regimens provided better survival results in KRAS-mutated mCRC patients and should be preferred over oxaliplatin. These findings should also be considered when investigating chemotherapy plus targeted agent combinations.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option? (Pubmed Central) - Jun 10, 2023
Patients receiving at least six courses had better overall survival than those who received fewer than six courses, regardless of the timing of treatment relative to surgery. Potential ways to increase chemotherapy adherence, such as administering treatment before surgery, should be considered.
- | albumin-bound paclitaxel / Generic mfg.
Journal, Metabolomic study, Metastases: Plasma Metabolomics Predicts Chemotherapy Response in Advanced Pancreatic Cancer. (Pubmed Central) - Jun 10, 2023
P=N/A
When stratified by the chemotherapy regimen, PD after 5-fluorouracil-based chemotherapy (e.g., FOLFIRINOX) was associated with decreased levels of amino acids (AAs)...These results demonstrate the feasibility of plasma metabolomics in a prospective cohort of advanced-PC patients for assessing the effect of enteral feeding as their primary source of nutrition. Metabolic signatures unique to FOLFIRINOX or gemcitabine/nab-paclitaxel may be predictive of a patient's response and warrant further study.
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion date, Trial primary completion date: NET-02: Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma (clinicaltrials.gov) - Jun 9, 2023
P2, N=102, Active, not recruiting, Sponsor: The Christie NHS Foundation Trust
Metabolic signatures unique to FOLFIRINOX or gemcitabine/nab-paclitaxel may be predictive of a patient's response and warrant further study. Trial completion date: Nov 2022 --> Dec 2023 | Trial primary completion date: Nov 2022 --> Dec 2023
- | veliparib (ABT-888) / AbbVie, Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Metastases: NRG-GI002: Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Jun 9, 2023
P2, N=363, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Nov 2022 --> Dec 2023 | Trial primary completion date: Nov 2022 --> Dec 2023 Trial completion date: Mar 2023 --> Mar 2024
- | Trial completion date, Trial primary completion date: Evaluation of a Folic Acid Wound Treatment (FAWT) for Chronic, Early-Stage Diabetic Foot Ulcer (DFU) Healing (clinicaltrials.gov) - Jun 8, 2023
P2, N=30, Recruiting, Sponsor: Joseph Boykin, MD
Trial completion date: Mar 2023 --> Mar 2024 Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Dec 2023
- || ASP3082 / Astellas
Enrollment change: 3082-CL-0101: A Study of ASP3082 in Adults With Advanced Solid Tumors (clinicaltrials.gov) - Jun 8, 2023
P1, N=356, Recruiting, Sponsor: Astellas Pharma Inc
Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Dec 2023 N=260 --> 356
- || pegvorhyaluronidase alfa (PEGPH20) / Halozyme, Tecentriq (atezolizumab) / Roche
P1/2 data, Journal, Metastases: Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. (Pubmed Central) - Jun 8, 2023
P1/2
The safety of atezolizumab plus PEGPH20 was consistent with each agent's known safety profile. (ClinicalTrials.gov Identifier: NCT03193190 and NCT03281369).